GSK3B and Alzheimer disease: Since the phosphorylation of τ-proteins is primarily dependent on GSK-3β and cyclin-dependent kinase 5 (CDK5, EC 2.7.11.22) [23], inhibition of GSK-3β and CDK5 is accepted as a promising strategy for the treatment of AD [24].